Amino Acid-Based PROTACs with Broad-Spectrum Antiviral Activity

A 1.5 KB dataset published by Tianai Fan in April 2026, detailing a series of novel Amino Acid–based PROTACs (AATacs) developed for antiviral research. The data describes compounds, including the representative compound N-6, designed to degrade viral polymerase via host E3 ligases. It includes results from in vitro and in vivo studies, such as potency measurements and mouse survival rates.

Use Cases

• Predict antiviral potency (nanomolar to picomolar) from compound structural features like conjugated acylthiourea and amino acid type.
• Model the relationship between compound structure (e.g., basic vs. hydrophobic amino acids) and broad-spectrum activity against multiple enteroviruses.
• Analyze in vivo efficacy metrics, such as the 60% survival rate in infected mice, against compound characteristics for candidate optimization.

Strengths

• Includes specific, high-potency results with nanomolar to picomolar activity reported for lead compounds.
• Contains in vivo validation data, including a concrete 60% survival rate for infected mice treated with compound N-6.

Limitations

• Extremely small dataset at 1.5 KB, indicating very limited scope and likely few data points or features.
• No column names or sample data are provided, making structural analysis and direct machine learning application difficult.

Provenance

Source

Tianai Fan via figshare.

Collection Method

Experimental research data from the development and testing of novel AATac compounds.

Freshness

Last updated in April 2026, indicating recent publication.